PA
CGNT icon

PharVision Advisers’s Cognyte Software CGNT Stock Holding History

PharVision Advisers’s Portfolio CGNT Stock Details CGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Buy
+13,978
New +$133K 2.31% 6
2026
Q1 		– Sell
-27,706
Closed -$260K – 201
2025
Q4 		$260K Buy
27,706
+2,995
+12% +$25.9K 0.13% 368
2025
Q3 		$208K Buy
+24,711
New +$219K 0.12% 485

Other funds holding CGNT

EC
Edenbrook Capital Mt. Kisco, New York $496M AUM 53.85% 1-Year Est. Return
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return
ACM
American Capital Management New York $2.23B AUM 28.03% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
YDMI
Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return
SM
Samjo Management New York $293M AUM 57.03% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PharVision Advisers's CGNT Position: Q2 2026 in Review

PharVision Advisers opened a new position in Cognyte Software (CGNT) in Q2 2026: 13,978 shares worth $123K. The stake represents 2.31% of the portfolio and ranks #6 among its holdings. This is a return to the name: PharVision Advisers previously reported a position in CGNT as recently as Q4 2025.

PharVision Advisers first reported a position in CGNT in Q3 2025 and has held it in 3 quarters since. The position peaked at $260K in Q4 2025. 135 funds tracked by Wall St. Rank hold CGNT as of Q2 2026.

  • PharVision Advisers held 13,978 shares of Cognyte Software worth $123K as of Q2 2026.
  • Cognyte Software was a new PharVision Advisers position in Q2 2026.
  • Cognyte Software made up 2.31% of PharVision Advisers's portfolio in Q2 2026, its #6 holding.
  • PharVision Advisers first reported a position in Cognyte Software in Q3 2025 and has held it in 3 quarters since.
  • PharVision Advisers's Cognyte Software position peaked at $260K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Cognyte Software as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.